Wednesday, January 7

6:00 p.m.-7:00 p.m.  OPENING SESSION/WELCOME/KEYNOTE PRESENTATION
                     Aventine DEFG
                     
                     MYC functions within a transcriptional regulatory network
                     Robert N. Eisenman, Fred Hutchinson Cancer Research Center, Seattle, WA

7:00 p.m.-9:00 p.m.  OPENING RECEPTION
                     Vicino Ballroom

Thursday, January 8

7:00 a.m.-8:00 a.m.  BREAKFAST
                     Grand Foyer

8:00 a.m.-10:00 a.m. PLENARY SESSION 1: MYC IN HUMAN CANCERS
                     Session Chairperson: Christine M. Eischen, Vanderbilt University, Nashville, TN
                     Aventine DEFG
                     
                     Dissection of the BRG1 and MYC/MAX biological connection and its use in
                     lung cancer therapeutics
                    Montserrat Sanchez-Cespedes, Institut d’Investigació Biomèdica de
                     Bellvitge, Barcelona, Spain

                     Role of MYC in germinal-center development and in lymphomagenesis
                     Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics,
                     New York, NY

                     Neuroblastoma as a paradigm of MYC(N) driven cancers
                     John M. Maris, The Children’s Hospital of Philadelphia, PA

                     Long noncoding RNA PVT1 potentiates MYC in human cancers with 8q24
                     gain*
                     Anindya Bagchi, University of Minnesota, Minneapolis, MN

                     Dynamic epigenetic regulation of glioblastoma tumorigenicity through a
                     LSD1-MYC-OLIG2 axis*
                     Clark Chen, University of California, San Diego, La Jolla, CA

10:00 a.m.-10:30 a.m. BREAK
                     Grand Foyer

*Short talks from proffered papers.
10:30 a.m.-12:30 p.m. **PLENARY SESSION 2: MYC AND METABOLISM/METABOLOMICS**
Session Chairperson: Javier León, Instituto de Biomedicina y Biotecnología de Cantabria, Santander, Spain
*Aventine DEFG*

**Targeting MYC-mediated cancer metabolism**
Chi Van Dang, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

**Recycling Myc to survive stress**
Maralice Conacci-Sorrell, Fred Hutchinson Cancer Research Center, Seattle, WA

**Metabolic reprogramming by MYC: Lessons learned from adenovirus**
Heather R. Christofk, UCLA School of Medicine, Los Angeles, CA

**MYC and mitochondrial metabolism in childhood neuroblastoma**
Marie Arsenian-Henriksson, Karolinska Institutet, Stockholm, Sweden

*There will be no short talks in this session.*

12:30 p.m.-2:30 p.m. **LUNCH ON OWN**

2:30 p.m.-4:30 p.m. **PLENARY SESSION 3: MYC FUNCTION AND PHOSPHORYLATION/UBIQUITINATION**
Session Chairperson: Lars-Gunnar Larsson, Karolinska Institutet, Stockholm, Sweden
*Aventine DEFG*

**Dynamic regulation of MYC and MYCN ubiquitination**
Iannis Aifantis, Howard Hughes Medical Institute/NYU School of Medicine, New York, NY

**Post-translational regulation of MYC’s oncogenic activity**
Rosalie C. Sears, Oregon Health & Science University, Portland, OR

**Control of mitochondrial transcription by MYC is essential for the survival of MYC-transformed cells**
Steven B. McMahon, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA

**Serine 62 phosphorylated MYC associates with nuclear lamins and its regulation by CIP2A is essential for proliferation induction in vivo**
Jukka Westermarck, Centre for Biotechnology and Department of Pathology, University of Turku, Turku, Finland

**Drugging MYC proteins through amphosteric inhibition of Aurora kinase A**
W. Clay Gustafson, University of California, San Francisco, CA

*Short talks from proffered papers.*

MYC: FROM BIOLOGY TO THERAPY
8:00 a.m.-10:00 a.m.  PLENARY SESSION 4: MODELING MYC IN MOUSE  
Session Chairperson: Louis Chesler, Institute of Cancer Research, Sutton, United Kingdom  
Aventine DEFG  

Mechanisms of MYC addiction  
Dean W. Felsher, Stanford University School of Medicine, Stanford, CA  

Modeling MYCN-driven tumors in human stem cells  
William A. Weiss, University of California, San Francisco, CA  

Investigating Myc function in mouse model of carcinogenesis  
Owen J. Sansom, Beatson Institute for Cancer Research, Glasgow, UK  

The MYC-MIZ1 interaction defines tumor identity  
Martine F. Roussel, St. Jude Children’s Research Hospital, Memphis, TN  

*There will be no short talks in this session.
10:30 a.m.-12:30 p.m.  PLENARY SESSION 5: MYC-DEPENDENT TRANSCRIPTION: AMPLIFICATION VERSUS GENE-SPECIFIC MODELS  Session Chairperson: Charles Lin, Dana-Farber Cancer Institute, Boston, MA  Aventine DEFG

Transcriptional regulation by physiological and oncogenic Myc levels  Martin Eilers, University of Würzburg, Würzburg, Germany

Control theory of MYC function and expression  David L. Levens, National Cancer Institute, Bethesda, MD

“Amplification versus Gene-Specific Models”: What is this session about?  Bruno Amati, Italian Institute of Technology and European Institute of Oncology, Milan, Italy

Targeting of CDK7 inhibits super-enhancer-associated oncogenic programs in MYCN-amplified tumor cells*  Edmond Chipumuro, Dana-Farber Cancer Institute, Boston, MA

Oncogenic MYC induces a dependency on mRNA processing in human breast cancer*  Thomas F. Westbrook, Baylor College of Medicine, Houston, TX

12:30 p.m.-3:00 p.m.  POSTER SESSION B with LUNCH  Vicino Ballroom

3:00 p.m.-5:00 p.m.  PLENARY SESSION 6: MYC AND EMERGING BIOLOGY  Session Chairperson: John M. Sedivy, Brown University, Providence, RI  Aventine DEFG

Mechanisms of MYC-driven genomic instability  Jean J. Gautier, Columbia University, New York, NY

Reduced expression of MYC increases longevity and enhances healthspan  John M. Sedivy, Brown University, Providence, RI

The MYC-microRNA pathway in B-cell neoplasms  Andrei Thomas-Tikhonenko, The Children’s Hospital of Philadelphia, PA

MYC-dependent translation makes an impact: Tailor-made protein expression for cancer development*  Davide Ruggero, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

The N-MYC transcriptional program driving the neuroendocrine prostate cancer phenotype*  David Rickman, Weill Cornell Medical College, New York, NY

*Short talks from proffered papers.

MYC: FROM BIOLOGY TO THERAPY
5:15 p.m.-6:30 p.m._short talks on targeting myc-driven cancers
Session Chairperson: Laura Soucek, Vall d'Hebron Institute of Oncology (VHIO),
Barcelona, Spain
Aventine DEFG

Facilitates Chromatin Transcription (FACT) acts in a forward feedback loop with MYCN and is a therapeutic target in neuroblastoma*
Daniel R. Carter, Children's Cancer Institute, Lowy Cancer Centre, University of New South Wales, Randwick, Australia

Preclinical validation of Myc inhibition by a new generation of Omomyc-based cell penetrating peptides*
Laura Soucek, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Cross-cancer evaluation of MYC synthetic lethal targets in The Cancer Genome Atlas*
Brady Bernard, Institute for Systems Biology, Seattle, WA

Selective targeting of MYC mRNA by chemically stabilized antisense oligonucleotides*
Christopher J. Ott, Dana-Farber Cancer Institute, Boston, MA

miR-17-92 mediates MYC oncogene addiction*
Yulin Li, Stanford University, Stanford, CA

EVENING OFF/DINNER ON OWN

*Short talks from proffered papers.
Saturday, January 10

7:00 a.m.-8:00 a.m.  BREAKFAST
Grand Foyer

8:00 a.m.-10:00 a.m.  PLENARY SESSION 7: MYC BEYOND CANCER
Session Chairperson: Laura A. Johnston, Columbia University Medical Center, New York, NY
Aventine DEFG

MYC is not required for the maintenance of pluripotency, but controls the balance between cellular metabolic activity and dormancy in ESCs and pre-implantation embryos
Andreas Trumpp, German Cancer Research Center, Heidelberg, Germany

An ancient signaling mechanism mediates the response of cells to fitness differences arising during tissue growth
Laura A. Johnston, Columbia University Medical Center, New York, NY

MYC in germinal center B cell physiology and pathology
Dinis Calado, London Research Institute, London, UK

HIF-2alpha regulates self-renewal of MYC dependent cancer stem cells*
Bikul Das, Stanford University School of Medicine, Stanford, CA

ERK2 binds to MYC promoter and induces MYC expression*
Javier León, Instituto de Biomedicina y Biotecnología de Cantabria, Santander, Spain

10:00 a.m.-10:30 a.m.  BREAK
Grand Foyer

10:30 a.m.-11:15 a.m.  KEYNOTE PRESENTATION
Aventine DEFG

Title to be announced
Peter K. Vogt, The Scripps Research Institute, La Jolla, CA
11:15 a.m.-12:45 p.m.  **PLENARY SESSION 8: THERAPEUTIC TRANSLATION**  
Session Chairperson: Marie Arsenian-Henriksson, Karolinska Institutet, Stockholm, Sweden  
_Aventine DEFG_

**Targeting MYC to kill cancers, not patients**  
Gerard I. Evan, University of Cambridge, Cambridge, UK

**Overcoming complexity: Targeting common vulnerabilities of MYC-driven cancers**  
Carla Grandori, Fred Hutchinson Cancer Research Center, Seattle, WA

**Inhibition of MYC transcriptional signaling**  
James E. Bradner, Dana-Farber Cancer Institute, Boston, MA

*There will be no short talks in this session.*

12:45 p.m.-1:00 p.m.  **CLOSING REMARKS/DEPARTURE**